Blueprint Medicines Corp

Blueprint Medicines — Technical Presentation (April 2024)

19 slides from Blueprint Medicines's technical presentation, Apr 25, 2024

  1. Slide 1: The Powerful Mast Cell: a promising target in treating allergic and inflammatory diseases

    THE POWERFUL MAST CELL a promising target in treating allergic and inflammatory diseases April 25, 2024

  2. Slide 2: Today's agenda and speakers

    Today’s agenda and speakers 2 WELCOME & INTRODUCTION Fouad Namouni, MD President, Research & Development A BLUEPRINT FOR TARGETING MAST CELLS Percy H. Carter, PhD, MBA Chief Scientific Officer MAST CELLS: POWERFUL DRIVERS OF DISEASE Becker Hewes, MD Chief Medical Officer Mariana Castells, MD, PhD Br

  3. Slide 3: Forward-looking statements

    Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for the company’s future business

  4. Slide 4: Blueprint's scientific vision for mast cell driven diseases

    Blueprint’s scientific vision for mast cell driven diseases Leverage deep understanding of mast cell biology Optimize target and modality approach Pursue “pipeline in a pill” therapies to capture multiple blockbuster opportunities Establish strong POC and rapidly de-risk development 4

  5. Slide 5: Mast cells are core drivers in a range of inflammatory diseases

    Mast cells are core drivers in a range of inflammatory diseases 5 • Central effector cell in many inflammatory diseases • Activation leads to release of multiple classes of inflammatory molecules with a broad range of physiological effects • KIT is a clinically validated master control switch for ma

  6. Slide 6: Blueprint is poised to drive a new wave of innovation in allergic and inflammatory disease

    Blueprint is poised to drive a new wave of innovation in allergic and inflammatory disease 6 Mast cells are key drivers of inflammatory responses, yet therapeutic interventions have focused on the mediators not the source. Directly inhibiting activation and degranulation of mast cells is an innovati

  7. Slide 7: Directly targeting the mast cell stands out as an attractive opportunity

    Directly targeting the mast cell stands out as an attractive opportunity in the allergy and inflammation space 7 Mast cell targeting Present Day TNF Histamine interleukins leukotrienes IgE KIT Note: bubble size is illustrative of the competitive intensity directed at each target Mediator Targeting M

  8. Slide 8: A Conversation with Dr. Becker Hewes and Dr. Mariana Castells: Mast Cells: Powerful Drivers of Disease

    A Conversation with Dr. Becker Hewes and Dr. Mariana Castells Mast Cells: Powerful Drivers of Disease

  9. Slide 9: Percy H. Carter: A Blueprint for Targeting Mast Cells

    Percy H. Carter A Blueprint for Targeting Mast Cells 21

  10. Slide 10: We are achieving R&D scale by leveraging our strengths

    We are achieving R&D scale by leveraging our strengths 22 PROVEN TRACK RECORD OF SUCCESS SCIENTIFIC EXPERTISE IN A/I & ONCOLOGY MODALITY AGNOSTIC DRUG DISCOVERY approved 2 medicines success rate from ~80% IND to POC development candidates 17 nominated AYVAKIT® (avapritinib) and elenestinib for syste

  11. Slide 11: KIT is a key regulator of mast cell activation and proliferation

    KIT is a key regulator of mast cell activation and proliferation 23 IgE Mast cell histamines cytokines prostaglandins Degranulation tryptase FceRI KIT Mast cells drive disease and exacerbate inflammation KIT regulates mast cell survival Blueprint track record of success in mast cell drug development

  12. Slide 12: Scientific leadership in KIT biology

    Scientific leadership in KIT biology 24 Elenestinib IDRX-73* BLU-808 MUTATED KIT WILD-TYPE KIT KIT D816V inhibitor (Systemic mastocytosis) Next-generation KIT D816V inhibitor (Systemic mastocytosis) KIT KIT exon 13 inhibitor (Gastrointestinal stromal tumor) Wild-type KIT inhibitor (Mast cell-mediate

  13. Slide 13: With BLU-808, tunable dosing could enable controlled reduction of mast cell number and activity

    With BLU-808, tunable dosing could enable controlled reduction of mast cell number and activity 25 BLU-808 Created with BioRender.com Wide range of therapeutic utility Lower dose BLU-808 could reduce MC activation Higher dose BLU-808 could reduce MC number

  14. Slide 14: Wild-type KIT inhibitor BLU-808 has first- and best-in-class potential

    Wild-type KIT inhibitor BLU-808 has first- and best-in-class potential aDetermined in a cellular assay. CSF1R, colony stimulating factor 1 receptor; FLT3, FMS-like tyrosine kinase 3; IC50, half-maximal inhibitory concentration; PDGFRA/B, platelet-derived growth factor receptor alpha/beta; pKIT, phos

  15. Slide 15: BLU-808 inhibits activation of human-derived CD34+ mast cells

    BLU-808 inhibits activation of human-derived CD34+ mast cells 27 Decreased CD63 expression and histamine release in treated human-derived CD34+ mast cells stimulated with IgE and anti-IgE BLU-808 is potent in two human-derived CD34+ mast cell assays • BLU-808 inhibits the expression of CD63 at the c

  16. Slide 16: BLU-808 inhibits degranulation of human-derived CD34+ mast cells

    BLU-808 inhibits degranulation of human-derived CD34+ mast cells • BLU-808 targets the source of histamine and other mediators by preventing mast cell degranulation • Mast cells were labeled in green to visualize degranulation. Following stimulation, the increase in green fluorescence indicated that

  17. Slide 17: BLU-808 can decrease mast cells in an exposure-dependent manner

    BLU-808 can decrease mast cells in an exposure-dependent manner • BLU-808 was administered for 7 days at different specific doses in rats • Mast cells were quantified by toluidine blue staining and showed a dose-dependent reduction • In vivo data in mouse model of asthma also support dose-dependent

  18. Slide 18: Potential to revolutionize the allergy/inflammation space with BLU-808

    Potential to revolutionize the allergy/inflammation space with BLU-808 30 Respiratory Skin Gastrointestinal Systemic Atopic dermatitis Asthma Allergic rhinitis Food allergies Eosinophilic esophagitis Mast cell activation syndrome BREADTH OF ADDITIONAL INDICATIONS PROOF OF CONCEPT Chronic urticaria H

  19. Slide 19: Thank you!

    Thank you! (blueprint,

Blueprint Medicines — Technical Presentation (April 2024) on 6ix